Harmony Biosciences Holdings (HRMY) Change in Receivables (2020 - 2026)
Harmony Biosciences Holdings (HRMY) posted Change in Receivables of $11.4 million for Q1 2026, up 395.94% sequentially from -$3.9 million in Q4 2025, and down 50.14% YoY from $22.9 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Change in Receivables (2020 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Change in Receivables for 7 years, with the latest figure at $11.4 million in Q1 2026.
- Quarterly Change in Receivables fell 50.14% year-over-year to $11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 91.42% YoY) and the FY2025 annual result came in at $13.8 million, up 54.66% from the prior year.
- Change in Receivables improved to $11.4 million in Q1 2026 per HRMY's latest filing, from -$3.9 million in the prior quarter.
- Over five years, Change in Receivables peaked at $22.9 million in Q1 2025 and troughed at -$13.0 million in Q2 2025.
- A 5-year average of $4.3 million and a median of $3.5 million in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables surged 2215.69% in 2023, then plunged 477.78% in 2025.
- Over 5 years, Change in Receivables stood at -$325000.0 in 2022, then soared by 2215.69% to $6.9 million in 2023, then slumped by 77.73% to $1.5 million in 2024, then tumbled by 352.38% to -$3.9 million in 2025, then soared by 395.94% to $11.4 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $11.4 million, -$3.9 million, and $7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.77 Mn |
| Jun 30, 2026 | 2.77 Mn |
| Mar 31, 2026 | 11.44 Mn |
| Mar 31, 2026 | 11.44 Mn |
| Dec 31, 2025 | -3.86 Mn |
| Dec 31, 2025 | -3.86 Mn |
| Sep 30, 2025 | 7.67 Mn |
| Sep 30, 2025 | 7.67 Mn |
| Jun 30, 2025 | -12.99 Mn |
| Jun 30, 2025 | -12.99 Mn |
| Mar 31, 2025 | 22.94 Mn |
| Mar 31, 2025 | 22.94 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | -1.66 Mn |
| Sep 30, 2024 | -1.66 Mn |
| Jun 30, 2024 | 3.44 Mn |
| Jun 30, 2024 | 3.44 Mn |
| Mar 31, 2024 | 5.58 Mn |
| Mar 31, 2024 | 5.58 Mn |